Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRA phase II master protocol of novel drug combinations in advanced or metastatic non-small cell lung cancer
2025-524843-11-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of ramucirumab, rilvegostomig, infliximab, mycophenolate mofetil and datopotamab deruxtecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events and serious adverse events and Objective response rate. Planned start Jun 2026; status: authorised.
02
Drugs
ramucirumabrilvegostomiginfliximabmycophenolate mofetildatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524843-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524843-11-00.